AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12869883
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg twice daily for 28 days
Trial: 8285627
Drug: Ceftriaxone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone at 2 g/day for 3 days
Trial: 8285627
Drug: Chloramphenicol at
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol at 50 mg/kg of body weight per day for 14 days
Trial: 29745059
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of TNFi treatment
Trial: 27791207
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Reflection Therapy (VRRT)
Trial: 18946891
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in general practice
Trial: 8728487
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg) administered at 1300 h
Trial: 8728487
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg) administered at 1800 h
Trial: 1794818
Drug: Sezolamide 1.8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sezolamide 1.8% twice daily
Trial: 6837251
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg perorally the night before operation and diazepam 0.2 mg per kg body weight perorally at 7.00 a.m. on the day of operation
Trial: 6837251
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg perorally the night before operation and morphine/scopolamine i.m. 1 h prior to operation
Trial: 6837251
Drug: No flunitrazepam
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No flunitrazepam given on the night before operation, morphine/scopolamine i.m. 1 h preoperatively
Trial: 29992486
Drug: Combined exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined exercise plus diet program (12-week, weekly aerobic exercise, 1200 kcal/day diet)
Trial: 29851107
Drug: FMT-S (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT-S (single faecal infusion via colonoscopy followed by a 14-day vancomycin course)
Trial: 29851107
Drug: FMT-M (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT-M (multiple faecal infusions plus a 14-day vancomycin course)
Trial: 29231361
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of ginger-isolated moxibustion and escitalopram (10 mg/day)
Trial: 17417658
Drug: Live-attenuated varicella
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated varicella zoster vaccine
Trial: 11772824
Drug: 0.075% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% ropivacaine with fentanyl 2 microg/mL
Trial: 11772824
Drug: 0.075% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% bupivacaine with fentanyl 2 microg/mL
Trial: 2540788
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Trial: 2540788
Drug: Eight courses
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Trial: 2540788
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Trial: 2540788
Drug: Eight courses
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Trial: 1078711
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (coronary bypass)
Trial: 28177719
Drug: Polyphenol beverage
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol beverage (1-1.5 L/day, approximately 400 mg of gallic acid equivalents per day)
Trial: 25116481
Drug: BMS-820836 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-820836 (0.5 mg)
Trial: 25116481
Drug: BMS-820836 (0.1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-820836 (0.1-4 mg)
Trial: 22915051
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL PS yoghurt drink consumed 45 min prior to a solid meal
Trial: 22915051
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL PS yoghurt drink consumed during a solid meal
Trial: 22915051
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL PS yoghurt drink consumed 45 min after a solid meal
Trial: 17135035
Drug: Estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 2 mg/day
Trial: 17135035
Drug: Estradiol 2
RxNorm normalized name: estradiol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 2 mg/day and norethisterone acetate 1 mg/day
Trial: 14561021
Drug: IV/PO moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/PO moxifloxacin 400 mg QD
Trial: 14561021
Drug: IV/PO amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID
Trial: 8635375
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg, qid)
Trial: 8635375
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (2 mg, qid)
Trial: 1727685
Drug: Naloxone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.15 mg/kg i.v.)
Trial: 1727685
Drug: Naloxone (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.075 mg/kg i.v.)
Trial: 27425824
Drug: NTP-CE (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTP-CE (topical panthenol-containing emollient)
Trial: 22311659
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied (670 nm, 5 mW, 2 J/cm², 16 min, 5 days)
Trial: 21083596
Drug: rabeprazole 5
RxNorm normalized name: RABEprazole 5 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 5 mg/day
Trial: 17470824
Drug: Adalimumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (160 mg at week 0 and 80 mg at week 2)
Trial: 12000496
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with 1% benzyl benzoate and 1% tannic acid
Trial: 12000496
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (first treatment)
Trial: 12000496
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (second treatment)
Trial: 2729162
Drug: Glucose absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose absorption in NIDDM subjects
Trial: 2729162
Drug: Glycine absorption
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine absorption in NIDDM subjects
Trial: 2729162
Drug: Glucose absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose absorption in healthy volunteers
Trial: 2729162
Drug: Glycine absorption
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine absorption in healthy volunteers
Trial: 30034
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Pindolol and 5 mg Clopamid (VKB 105)
Trial: 28139100
Drug: Ozurdex® implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozurdex® implant (PRN group)
Trial: 28139100
Drug: Ozurdex® implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozurdex® implant (fixed group)
Trial: 23381501
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (immediate treatment)
Trial: 23381501
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (no treatment for 3 months)
Trial: 18206037
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of anisodamine (200 microg/ml)
Trial: 18206037
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Control group B)
Trial: 18206037
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of anisodamine
Trial: 9815053
Drug: Intravenous famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous famotidine (gastric acid inhibition)
Trial: 8715223
Drug: Lugol daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lugol daily dressings applied for 10 consecutive days
Trial: 340158
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 to 160 mg daily
Trial: 30565426
Drug: β-alanine (BA)
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-alanine (BA) supplementation (12 g/day for 14 days)
Trial: 27286893
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2 mg)
Trial: 24996893
Drug: Aspheric toric
RxNorm normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspheric toric intraocular lens (Lentis L‐312T)
Trial: 24996893
Drug: Aspheric nontoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspheric nontoric intraocular lens (Lentis L‐312) with opposite clear corneal incision (OCCI)
Trial: 17587273
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (50 mg/kg/day)
Trial: 11807965
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg hawthorn extract
Trial: 11807965
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Mg
Trial: 11807965
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 600 mg Mg and 500 mg hawthorn extract
Trial: 88753
Drug: 5‐FU chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU chemotherapy (12 mg/kg daily for 4 days, then 6 mg/kg on alternate days, followed by 12 mg/kg weekly for 1 year)
Trial: 28399551
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for degenerative spondylolisthesis (DS) including instrumented fusion (72%), noninstrumented fusion (21%), and decompression alone (7%).
Trial: 25460264
Drug: Baseline standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline standard inpatient treatment
Trial: 23480783
Drug: Metformin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (n = 24)
Trial: 23480783
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus Simvastatin (n = 18)
Trial: 18957487
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 or 6 mg/kg) plus methotrexate (MTX)
Trial: 16763547
Drug: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone (0.16 mg/kg, subcutaneous injection, 3 cycles of 10 days over 3 months)
Trial: 16763547
Drug: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
Trial: 15123028
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam 0.2 mg/kg
Trial: 11304782
Drug: Intravenous fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fluorouracil plus leucovorin (5‐FU/LV)
Trial: 8306013
Drug: Oxytocin plus
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin plus ergometrine (Syntometrine: 5 units of oxytocin with 0.5 mg of ergometrine)
Trial: 3521532
Drug: Haloperidol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (n = 21), mean dose 7.24 mg, 4 to 16 mg range
Trial: 3521532
Drug: Amitriptyline (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (n = 20), mean dose 147.62 mg, 100 to 175 mg range
Trial: 26700937
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of atorvastatin once daily for 2 years
Trial: 26700937
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo once daily for 2 years
Trial: 22936298
Drug: Polyether (PE:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyether (PE: Impregum Penta H/L DuoSoft Quick, 3 M ESPE) with manufacturer's recommended working time
Trial: 17006324
Drug: CsA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA plus atorvastatin
Trial: 17006324
Drug: TRL plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRL plus atorvastatin
Trial: 3532602
Drug: Heat-stable 17D
RxNorm normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stable 17D yellow fever vaccine
Trial: 3532602
Drug: Non-stabilized yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-stabilized yellow fever vaccine
Trial: 24606601
Drug: Self-management group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management group intervention (eight weekly sessions, 90 minutes each)
Trial: 9438888
Drug: Popliteal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Popliteal block (30 ml of alkalinized 3% chloroprocaine) and posterior cutaneous nerve of the thigh block (10 ml of 1% lidocaine)
Trial: 9438888
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (65 mg of 5% hyperbaric lidocaine)
Trial: 8235870
Drug: Extension treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension treatment
Trial: 8235870
Drug: Flexion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexion treatment
Trial: 8235870
Drug: Placebo-control treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-control treatment
Trial: 3680597
Drug: 4-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-g dose of mezlocillin
Trial: 3680597
Drug: 5-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-g dose of mezlocillin
Trial: 20197582
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy (including antiplatelet and antithrombin agents)
Trial: 15739719
Drug: Daily 15‐minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 15‐minute oral stimulation program for 10 days before the start of oral feedings
Trial: 15739719
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral stimulation program)
Trial: 14969216
Drug: Immediate non-occlusal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate non-occlusal loading of dental implants
Trial: 8635262
Drug: LDL-apheresis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-apheresis plus medication (simvastatin 40 mg/day)
Trial: 8635262
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (simvastatin 40 mg/day)
Trial: 8635262
Drug: LDL-apheresis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-apheresis plus medication
Trial: 21556784
Drug: Telephonic quitline
RxNorm normalized name: quinoline yellow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephonic quitline intervention (counseling and nicotine replacement therapy)
Trial: 19382469
Drug: Integrative medical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative medical regimen (IMR) - Jiangya Capsule (JYC) and Nimodipine (ND)
Trial: 12365016
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with mitomycin C (6 mg/m(2) i.v.) and 5‐fluorouracil (310 mg/m(2) i.v.) for 5 consecutive days during postoperative Weeks 1 and 3, followed by 5‐FU (100 mg/m(2) orally) daily from postoperative Week 5 until disease recurrence.
Trial: 12365016
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with mitomycin C and 5‐fluorouracil.
Trial: 7648285
Drug: Zidovudine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (200 mg every 8 h for 3 days)
Trial: 7648285
Drug: Didanosine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine (200 mg every 12 h for 3 days)
Trial: 2649867
Drug: Oxytetracycline, Doxycycline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytetracycline, Doxycycline, Rifampin (oral monotherapy)
Trial: 2649867
Drug: TMP/SMX (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX (oral monotherapy)
Trial: 2649867
Drug: Rifampin plus
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin plus Oxytetracycline (combined oral therapy)
Trial: 2649867
Drug: Rifampin plus
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin plus TMP/SMX (combined oral therapy)
Trial: 2649867
Drug: Oxytetracycline plus
RxNorm normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytetracycline plus TMP/SMX (combined oral therapy)
Trial: 2649867
Drug: Oral monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monotherapy combined with Streptomycin
Trial: 2649867
Drug: Oral monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monotherapy combined with Gentamicin
Trial: 24825404
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (220 mg/d)
Trial: 15083598
Drug: Intravenous glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycoprotein IIb/IIIa inhibitors
Trial: 23745947
Drug: Crushed morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed morphine sulfate controlled-release (CR) tablets
Trial: 23745947
Drug: Crushed morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed morphine sulfate and naltrexone hydrochloride extended-release capsules (MSN)
Trial: 14618043
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day MgSO(4) infusion in 100 mL 0.9 NaCl solution (25 mL/hr) for 4 days after surgery
Trial: 14618043
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL 0.9 NaCl solution (25 mL/hr)
Trial: 14618043
Drug: MgSO(4) infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MgSO(4) infusion
Trial: 11051622
Drug: Pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 200 mg bd for 7 days
Trial: 11051622
Drug: Pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 200 mg bd for 3 days
Trial: 11051622
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg bd for 3 days
Trial: 3160915
Drug: Ketanserin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin, 40 mg
Trial: 3160915
Drug: Ketoconazole, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole, 400 mg
Trial: 27823876
Drug: 0.2 mL
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL intranasal midazolam